Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
Stopped See termination reason in detailed description.
Conditions
- Cardiovascular Disease
- Cerebrovascular Disorders
Sponsor
Pfizer